MVA-BN-Brachyury-TRICOM
AXP000185.1 · Cancer vaccine
- Platform
- MVA-BN (with fowlpox boost)
- Targets
- TBXT
- Originator
- Bavarian Nordic
- Sponsor
- Bavarian Nordic
Names
| Name | Type | Source |
|---|---|---|
| MVA-BN-Brachyury-TRICOM | preferred name | curator |
| BN-Brachyury | code | curator |
| FPV-Brachyury-TRICOM | code | ncit |
| MVA-BN-Brachyury | code | ncit |
| MVA Brachyury-TRICOM ambiguous | synonym | ncit |
Virus
- Role
- Vaccine vector
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- MVA-BN prime; fowlpox (FPV-Brachyury) boost
- Replication
- non replicating
- Modifications
- brachyury and TRICOM cassettes in MVA-BN
- Transgenes
- TBXT, CD80, ICAM1, CD58
- Route
- subcutaneous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C148400
- FDA UNII
- GD1ZWN2I2Y
Approvals
No regulatory approval recorded.
Clinical trials (6)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05445882 | N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer | Withdrawn | Phase 2 | 2024-04-01 | 2024-04-01 | 0 | Castration Resistant Prostate Cancer |
| NCT04134312 | A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer | Completed | Phase 1 | 2020-01-08 | 2021-01-12 | 13 | Solid Metastatic Tumor |
| NCT04020094 | Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer | Withdrawn | Phase 2 | 2019-11-20 | 2021-04-09 | 0 | Prostate Adenocarcinoma |
| NCT03595228 | BN Brachyury and Radiation in Chordoma | Completed | Phase 2 | 2018-10-31 | 2021-12-10 | 29 | Chordoma |
| NCT03493945 | Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) | Completed | Phase 1/2 | 2018-05-01 | 2024-10-08 | 59 | Advanced Solid Tumor; Metastatic Castration-resistant Prostate Cancer; Non-metastatic Castration-resistant Prostate Cancer; Prostate Cancer; Prostate Neoplasm; Solid Tumor |
| NCT03349983 | Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury) | Completed | Phase 1 | 2018-01-08 | 2020-06-13 | 11 | Safety Issues |
Unconfirmed matches (2)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT04296942 | BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) | Terminated | Phase 1 | 2021-05-04 | 2021-10-22 | 1 | Breast Cancer; HER2+ Breast Cancer; Hormone Receptor Negative Breast Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer | name in title: BN-Brachyury |
| NCT02179515 | Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM) | Completed | Phase 1 | 2014-06-28 | 2017-04-06 | 38 | Breast Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer; Tumors (Others) | intervention named: MVA Brachyury-TRICOM |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42498485 | Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer. | Journal for immunotherapy of cancer | 2026 | cited by trial NCT03493945 |
| PMID 38985843 | A phase 2 study of a brachyury-targeting vaccine in combination with radiation therapy for the treatment of advanced chordoma. | Cancer | 2024 | name in abstract: MVA-BN-Brachyury |
| PMID 33602696 | Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve. | Journal for immunotherapy of cancer | 2021 | cited by trial NCT03493945 |
| PMID 34266694 | Chordoma: Current status, problems, and future directions. | Current problems in cancer | 2021 | cited by trial NCT03595228 |
| PMID 34479925 | Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. | Journal for immunotherapy of cancer | 2021 | cited by trial NCT04134312 |
| PMID 31876334 | Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors. | The oncologist | 2020 | cited by trial NCT03349983 |
| PMID 30227893 | Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer. | Journal for immunotherapy of cancer | 2018 | cited by trial NCT03493945 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 33747894 | Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer. | Frontiers in oncology | 2020 | name in abstract: BN-Brachyury |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| ZIABC010598 | Human Immune Responses to Tumor Antigens for Cancer Immunotherapy | DIVISION OF BASIC SCIENCES - NCI | SCHLOM, JEFFREY | 2012–2025 | name in abstract: MVA-BN-Brachyury-TRICOM |
| ZIABC010425 | Strategies for Cancer Immunotherapy Clinical Trials | DIVISION OF BASIC SCIENCES - NCI | SCHLOM, JEFFREY | 2009–2023 | name in abstract: MVA-BN-Brachyury-TRICOM |
| ZIABC011865 | Breast and Other Carcinoma Clinical Trials Using Immunotherapies | DIVISION OF BASIC SCIENCES - NCI | GATTI-MAYS, MARGARET | 2019–2020 | name in abstract: MVA-BN-Brachyury |
Notes
MVA-BN-Brachyury prime with FPV-Brachyury-TRICOM boosts (NCIt C148402), encoding brachyury (TBXT) and TRICOM; phase 1/2 at the NCI in chordoma and other solid tumours. NCIt also holds a separate earlier concept 'MVA Brachyury-TRICOM' (C116777) whose relationship to this construct is unclear; that name is listed as an ambiguous alias.
How to cite
MVA-BN-Brachyury-TRICOM (AXP000185.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000185.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.